[Hot Stock] Ilyang Pharmaceutical's 'Supect' Soars on News of Phase 3 Clinical Trial for COVID-19 Treatment
[Asia Economy Reporter Geum Bo-ryeong] Ilyang Pharmaceutical's new drug 'Supect' has surged for two consecutive days following news that it received approval for Phase 3 clinical trials as a treatment for COVID-19.
As of 10:03 AM on the 29th, Ilyang Pharmaceutical's stock price rose 19.16% (8,200 KRW) from the previous close to 50,900 KRW. The previous day, Ilyang Pharmaceutical also hit the daily limit up.
Hot Picks Today
![About 100 Trillion Won at Stake... "Samsung Strike Is an Unprecedented Opportunity" as Prices Surge 20% [Taiwan Chip Column]](https://cwcontent.asiae.co.kr/asiaresize/93/2026051416263163580_1778743590.jpg)
About 100 Trillion Won at Stake... "Samsung Strike Is an Unprecedented Opportunity" as Prices Surge 20% [Taiwan Chip Column]
- "Anyone Who Visited the Room Salon, Come Forward"… Gangnam Police Station Launches Full Staff Investigation After New Scandal
- What Happened in the Maldives, a Top Resort Destination... Five Tourists Dead
- Woman in Her 50s Found Dead 28 Days After Going Missing on Bukhansan Mountain
- "Heading for 2 Million Won": The Company the Securities Industry Says Not to Doubt [Weekend Money]
On the previous day, Ilyang Pharmaceutical announced that Supect received approval from the Russian government to conduct Phase 3 clinical trials to verify its effectiveness as a COVID-19 treatment. The clinical trials will be conducted by the Russian pharmaceutical company Alfarm.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
